Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of adjuvant capecitabine after proximal pancreatico-duodenectomy in pancreatic adenocarcinoma
2008-008476-14Phase 4Completed
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
- Start
- Jun 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of capecitabine in pancreatic adenocarcinoma (PDAC), sponsored by Cambridge University Hospitals NHS Foundation Trust. Primary endpoints: Pharmacokinetic parameters of capecitabine and Toxicity profile and dose-limiting toxicities of capecitabine. Started Jun 2009; status: completed.
02
Drugs
capecitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2008-008476-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-008476-14.